Literature DB >> 8777997

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose.

A Ceriello1, C Taboga, L Tonutti, R Giacomello, L Stel, E Motz, M Pirisi.   

Abstract

It has been previously demonstrated that hyperglycaemia activates haemostasis; diabetes mellitus is considered a thrombosis-prone state. Acarbose, by inhibiting dietary carbohydrate absorption, reduces post-meal hyperglycaemia. In this study we evaluated the effect of post-meal hyperglycaemia on two markers of coagulation activation: prothrombin fragments 1 + 2 and D-dimer. Seventeen non-insulin-dependent diabetic patients maintained on diet therapy alone were randomly assigned to receive- with a cross-over study design-acarbose (100 mg orally) or placebo before a standard meal. Blood samples for measurement of plasma glucose, insulin, prothrombin fragments 1 + 2 and D-dimer were drawn at 0, 60, 120 and 240 min. After both placebo and acarbose, hyperglycaemia and hyperinsulinaemia which followed a standard meal were accompanied by a significant increase of plasma concentration of prothrombin fragments 1 + 2 and D-dimer in comparison to their baseline values. Acarbose administration significantly reduced the rise of glucose, insulin, prothrombin fragments 1 + 2 and D-dimer from 0 to 240 min in comparison to placebo. We conclude that post-meal hyperglycaemia, at the level reached by many diabetic patients on diet therapy alone, induces a coagulation activation. Acarbose, by decreasing post-meal hyperglycaemia, may be useful in reducing meal-induced activation of haemostasis in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777997     DOI: 10.1007/bf00400679

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

1.  Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

Authors:  M J Garcia; P M McNamara; T Gordon; W B Kannel
Journal:  Diabetes       Date:  1974-02       Impact factor: 9.461

2.  Generation of the combined prothrombin activation peptide (F1-2) during the clotting of blood and plasma.

Authors:  D L Aronson; L Stevan; A P Ball; B R Franza; J S Finlayson
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

Review 3.  Vascular thrombosis in type II diabetes mellitus.

Authors:  J A Colwell
Journal:  Diabetes       Date:  1993-01       Impact factor: 9.461

Review 4.  Detection and relevance of crosslinked fibrin derivatives in blood.

Authors:  H Graeff; R Hafter
Journal:  Semin Thromb Hemost       Date:  1982-01       Impact factor: 4.180

5.  Hyperglycemia may determine fibrinopeptide A plasma level increase in humans.

Authors:  A Ceriello; D Giugliano; A Quatraro; P Dello Russo; E Marchi; R Torella
Journal:  Metabolism       Date:  1989-12       Impact factor: 8.694

6.  Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems.

Authors:  F A Hunt; D B Rylatt; R A Hart; P G Bundesen
Journal:  Br J Haematol       Date:  1985-08       Impact factor: 6.998

7.  Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.

Authors:  E Ernst; K L Resch
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

8.  Blood glucose may condition factor VII levels in diabetic and normal subjects.

Authors:  A Ceriello; D Giugliano; A Quatraro; P Dello Russo; R Torella
Journal:  Diabetologia       Date:  1988-12       Impact factor: 10.122

9.  Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon.

Authors:  R L Jones; C M Peterson
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  17 in total

1.  Factor V Leiden mutation and Japanese NIDDM.

Authors:  M Odawara; K Yamashita
Journal:  Diabetologia       Date:  1997-11       Impact factor: 10.122

Review 2.  Prandial hyperglycemia: is it important to track and treat?

Authors:  Markolf Hanefeld; Frank Schaper
Journal:  Curr Diab Rep       Date:  2005-10       Impact factor: 4.810

3.  Hypoglycemic and hypolipidemic effects of samnamul (shoot of Aruncus dioicus var. kamtschaticus Hara) in mice fed a high-fat/high-sucrose diet.

Authors:  Jung-In Kim; Jeong-A Yun; Yoo-Kyung Jeong; Hee-Jin Baek
Journal:  Food Sci Biotechnol       Date:  2018-06-08       Impact factor: 2.391

4.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.

Authors:  Helen Vlassara; Weijing Cai; Jill Crandall; Teresia Goldberg; Robert Oberstein; Veronique Dardaine; Melpomeni Peppa; Elliot J Rayfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

Review 5.  Drugs for cardiovascular risk reduction in the diabetic patient.

Authors:  D S Bell
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

Review 6.  Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Authors:  André J Scheen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Who should benefit from the use of alpha-glucosidase inhibitors?

Authors:  Ariane Godbout; Jean-Louis Chiasson
Journal:  Curr Diab Rep       Date:  2007-10       Impact factor: 4.810

Review 8.  Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?

Authors:  Guillaume Charpentier; Jean-Pierre Riveline; Dured Dardari; Michel Varroud-Vial
Journal:  Drugs       Date:  2006       Impact factor: 9.546

9.  Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia.

Authors:  Itamar Raz; Antonio Ceriello; Peter W Wilson; Chakib Battioui; Eric W Su; Lisa Kerr; Cate A Jones; Zvonko Milicevic; Scott J Jacober
Journal:  Diabetes Care       Date:  2011-05-18       Impact factor: 19.112

10.  Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.

Authors:  Christoph Rosak; Gabriele Mertes
Journal:  Diabetes Metab Syndr Obes       Date:  2012-10-12       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.